Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABT-165 + FOLFIRI
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
ABT-165 + FOLFIRI is a combination regimen comprised of ABT-165 (also known as dilpacimab), a dual-variable domain immunoglobulin monoclonal antibody targeting both delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF), and the standard chemotherapy regimen FOLFIRI, which includes folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. ABT-165 inhibits the DLL4/Notch and VEGF pathways to block tumor angiogenesis and growth, while FOLFIRI works by disrupting DNA synthesis and cell division in rapidly proliferating cancer cells. This drug combination has been studied primarily for metastatic colorectal cancer and is being investigated in advanced solid tumors and other cancers sensitive to anti-angiogenic and cytotoxic chemotherapy[1][2][3][5].
- Other names
- dilpacimab + FOLFIRI
02
Targets
Beyond the preview
Go deeper on ABT-165 + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABT-165 + FOLFIRI.